SSG
HAE icon

Summit Securities Group’s Haemonetics HAE Stock Holding History

Summit Securities Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-271
Closed -$15.3K – 1245
2026
Q1 		$15.3K Buy
+271
New +$17.6K ﹤0.01% 579
2015
Q3 		– Sell
-1,190
Closed -$49K – 423
2015
Q2 		$49K Buy
+1,190
New +$50.2K 0.02% 191

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Securities Group's HAE Position: Q2 2026 in Review

Summit Securities Group sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 271 shares — an estimated $15.3K sold.

Summit Securities Group first reported a position in HAE in Q2 2015 and held it in 2 quarters. The position peaked at $49K in Q2 2015. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Summit Securities Group reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 271 Haemonetics shares in Q2 2026, an estimated $15.3K.
  • Summit Securities Group first reported a position in Haemonetics in Q2 2015 and held it in 2 quarters.
  • Summit Securities Group's Haemonetics position peaked at $49K in Q2 2015.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.